Tisdag 26 November | 08:49:40 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-28 13:30 Bokslutskommuniké 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-13 - Kvartalsrapport 2024-Q2
2024-05-14 - Kvartalsrapport 2024-Q1
2024-05-06 - X-dag ordinarie utdelning PTRK 0.00 SEK
2024-05-03 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-04 - X-dag ordinarie utdelning PTRK 0.00 SEK
2023-05-03 - Årsstämma
2023-05-02 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-26 - Kvartalsrapport 2022-Q1
2022-05-04 - X-dag ordinarie utdelning PTRK 0.00 SEK
2022-05-03 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-07-28 - Kvartalsrapport 2021-Q2

Beskrivning

LandStorbritannien
ListaFirst North Stockholm
SektorInformationsteknik
IndustriProgramvara
Physitrack är verksamt inom hälsovårdssektorn. Bolaget är specialiserat inom sjukgymnastik. Produktportföljen inkluderar digitala vårderbjudanden till företag via SaaS-lösningar. Utöver huvudverksamheten erbjuds även personlig service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa och Nordamerika. Physitrack grundades 2012 och har sitt huvudkontor i London.
2023-11-14 08:00:00

Celebrating another successful quarter of growth, with adjusted EBITDA increasing to EUR 1.1m for the quarter showcasing the Group’s continued dedication to financial excellence and sustainable success.

Quarter ended - Jul - Sep 2023

  • Revenue increased by 14 per cent from the comparative period in 2022 to generate total sales of EUR 3.9m (EUR 3.4m). On an organic basis revenue grew by 17 per cent. This organic growth was achieved in both the Lifecare (11 per cent) and Wellness (29 per cent) divisions.
  • Adjusted EBITDA of EUR 1.1m (EUR 0.9m) was generated resulting in an Adjusted EBITDA margin of 27 per cent (27 per cent).
  • Adjusted operating profit of EUR 0.1m (EUR 0.2m) was generated resulting in a margin of 3 per cent (6 per cent).
  • Adjusted ordinary and diluted loss per share totalled EUR 0.00 (EUR 0.01).
  • Cashflow generated from operations before the payment of adjusting items equalled EUR 0.9m (EUR 0.5m).
  • Free cash flow for the quarter was a net outflow of EUR 0.3m (outflow EUR 0.9m).

Nine months ended - Jan - Sep 2023

  • Revenue increased by 26 per cent from the comparative period in 2022 to generate total sales of EUR 11.3m (EUR 9.0m). On an organic proforma basis revenue grew by 27 per cent. This proforma growth was achieved in both the Lifecare (13 per cent) and Wellness (61 per cent) divisions.
  • Adjusted EBITDA of EUR 2.9m (EUR 2.6m) was generated resulting in an Adjusted EBITDA margin of 26 per cent (29 per cent).
  • Adjusted operating profit of EUR 0.3m (EUR 1.0m) was generated resulting in a margin of 3 per cent (11 per cent).
  • Adjusted ordinary and diluted profit per share totalled EUR 0.01 (EUR 0.05).
  • Cashflow generated from operations before the payment of adjusting items equalled EUR 2.1m (EUR 1.7m).

Operational highlights

  • The Group has always been at the forefront of technological innovation and is pleased to announce further enhancements to the Physitrack platform through the integration and utilisation of AI technology for a range of features and content production, further enhancing customer engagement and practical use.
  • We have made significant enhancements to the existing Champion Health platform, streamlining user interfaces, improving performance, and introducing new features to enhance the overall user experience. The platform is now in a position which will allow it to be localised and rolled out to non-English speaking territories.
  • Champion Health secured significant contracts during the quarter including a multi-year deal with E.ON, the UK’s largest energy provider; Healix and Anaplan. These agreements support the continued growth of the Wellness division.
  • With an unwavering commitment to an efficient and sustainable business model, the Group's strategy continues to focus on revenue stream enhancement and cost optimisation across all divisions, resulting in a EUR 0.1m quarter on quarter increase in adjusted EBITDA, to EUR 1.1m and an expansion of adjusted EBITDA margins to 27%. Our ongoing plan includes the continued strategic deployment of AI tools throughout the organisation to ensure peak operational and cost efficiency.
  • The Group re-confirms that it is expected there will be no further deferred contingent consideration payments for the remainder of the financial year, and no capital raising via share issuance or debt.

Henrik Molin, Co-founder and CEO of Physitrack PLC, commented:
“I am proud to see our amazing teams continuing to thrive and remaining resilient in achieving our targets and achieving our mission of Elevating the World’s Wellbeing, in an unpredictable macroeconomic environment for many of our target markets.”

Group Key Performance Indicators:


3 Month period ended9 Month period endedYear ended
EUR (€), unless otherwise stated30 Sep 2330 Sep 2230 Sep 2330 Sep 2231 Dec 22
Revenue3,851,2303,365,22111,336,9218,993,26112,510,371
Prior period revenue growth (%)1472266557
Organic revenue / Proforma revenue growth (%)1728273027
EBITDA825,654714,4302,269,3341,249,6922,543,318
Operating (loss) / profit(98,942)2,789(364,347)(367,762)109,387
Adjusted EBITDA1,051,111917,0012,926,8572,569,9353,446,475
Adjusted EBITDA margin (%)2727262928
Adjusted operating profit126,515205,360293,177952,4811,012,544
Adjusted operating margin (%)363118
Adjusted earnings per share0.000.010.010.050.06
Operating cashflow before adjusting items852,284454,3082,076,8421,706,7262,897,554
% of revenue which is subscription7574727271

Webcast conference:
November 14, 2023, at 10.00 CEST. The presentation will be held in English and will be available on https://www.physitrackgroup.com/investors/reports-presentations after the webcast conference.

Speakers:
Henrik Molin, CEO
Charlotte Goodwin, CFO

Link to webcast registration:
https://us06web.zoom.us/webinar/register/WN_XBOR6-IySomnd5qguNH8Dw

Participants will be able to ask questions through the web chat.

Enquiries regarding this announcement should be addressed to:
Henrik Molin, CEO, Physitrack.
+44 208 133 9325
ir@physitrack.com
media@physitrack.com

About Physitrack
Physitrack PLC, founded in 2012, is a global digital healthcare provider, focused on the B2B wellness and virtual-first care markets. With staff with 12 nationalities on four continents, customers in 17 time zones, and end users in 187 countries, Physitrack is a truly global company.

The company has two business lines:
1. Lifecare – SaaS platform tailored mainly to physiotherapy and musculoskeletal care, enabling practitioners to deliver clinical home exercises, education prescription, outcomes tracking, triaging and Telehealth.
2. Wellness / Champion Health – SaaS platform for Employee Wellness and care powered by a combination of world-leading technology and wellness professionals based in the United Kingdom, Germany and the Nordics.

Physitrack PLC is headquartered in London, United Kingdom, and listed on Nasdaq First North Premier Growth Market (PTRK).

Visit us at https://www.physitrackgroup.com/

This information is such information as Physitrack PLC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on November 14, at 8.00 am CEST.